论文部分内容阅读
目的:分析瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效。方法:对自2014年11月至2015年10月在我院治疗的87例老年冠心病合并高脂血症患者为研究对象,按自愿用药方式分组后采用不同的药物进行治疗,并对治疗后的评价指标内容进行对比分析。结果:采用瑞舒伐他汀钙治疗的观察组的TC、TG、LDL-C、HDL-C均优于采用辛伐他汀治疗的对照组,两组患者治疗前后的评价指标内容均得到有效改善,比价差异值P<0.05;观察组的不良反应发生率为6.67%优于对照组的14.29%,比较差异P<0.05。均具有统计学意义。结论:采用瑞舒伐他汀治疗老年冠心病合并高脂血症有更好的改善临床指标效果,疗效更为显著,且不良反应较低,值得临床推广应用。
Objective: To analyze the effect of rosuvastatin calcium on senile coronary heart disease complicated with hyperlipidemia. Methods: From November 2014 to October 2015 in our hospital for treatment of 87 elderly patients with coronary heart disease with hyperlipidemia as the research object, according to the voluntary way to use different drugs after treatment, and after treatment The contents of the evaluation index for comparative analysis. Results: TC, TG, LDL-C and HDL-C in the observation group treated with rosuvastatin calcium were better than those in the control group treated with simvastatin. The evaluation indexes of both groups before and after treatment were effectively improved, P <0.05; the incidence of adverse reactions in the observation group was 6.67%, which was 14.29% of that in the control group, with a significant difference of P <0.05. All have statistical significance. Conclusion: The use of rosuvastatin in elderly patients with coronary heart disease complicated with hyperlipidemia has better clinical effect, the effect is more significant, and the adverse reaction is low, worthy of clinical application.